Search research articles
Contact Us
Filters
Showing results (51-60 of 77) with videos related to
Page
of 8
Sort By:
Leukemia & Lymphoma
|
August 20, 2011
Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network
Martin Dreyling, Hanneke C Kluin-Nelemans, Sílvia Beà, et al.
Blood Advances
|
April 15, 2026
Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up
Roger G Owen, Helen McCarthy, Shirley D'Sa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 2025
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma
Michael Wang, David Salek, David Belada, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 13, 2012
Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma
Véronique Leblond, Steve Johnson, Sylvie Chevret, et al.
Lancet (London, England)
|
December 18, 2015
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study
Martin Dreyling, Wojciech Jurczak, Mats Jerkeman, et al.
Hematological Oncology
|
August 7, 2019
A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL
Toby A Eyre, Catherine Hildyard, Angela Hamblin, et al.
British Journal of Haematology
|
February 23, 2021
Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients
Rory McCulloch, David Lewis, Nicola Crosbie, et al.
The Lancet. Oncology
|
February 23, 2016
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial
Marek Trněný, Thierry Lamy, Jan Walewski, et al.
Blood
|
June 11, 2015
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
Michael L Wang, Kristie A Blum, Peter Martin, et al.
The Journal of Rheumatology
|
March 3, 2004
Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR
John A Snowden, Jakob Passweg, John J Moore, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 77) with videos related to
Sort By:
Page
of 8
Leukemia & Lymphoma
|
August 20, 2011
Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network
Martin Dreyling, Hanneke C Kluin-Nelemans, Sílvia Beà, et al.
Blood Advances
|
April 15, 2026
Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up
Roger G Owen, Helen McCarthy, Shirley D'Sa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 2025
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma
Michael Wang, David Salek, David Belada, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 13, 2012
Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma
Véronique Leblond, Steve Johnson, Sylvie Chevret, et al.
Lancet (London, England)
|
December 18, 2015
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study
Martin Dreyling, Wojciech Jurczak, Mats Jerkeman, et al.
Hematological Oncology
|
August 7, 2019
A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL
Toby A Eyre, Catherine Hildyard, Angela Hamblin, et al.
British Journal of Haematology
|
February 23, 2021
Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients
Rory McCulloch, David Lewis, Nicola Crosbie, et al.
The Lancet. Oncology
|
February 23, 2016
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial
Marek Trněný, Thierry Lamy, Jan Walewski, et al.
Blood
|
June 11, 2015
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
Michael L Wang, Kristie A Blum, Peter Martin, et al.
The Journal of Rheumatology
|
March 3, 2004
Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR
John A Snowden, Jakob Passweg, John J Moore, et al.
Page
of 8